SCHEMBL823609

SCHEMBL823609

COCCOc1nc(N)nc2ccc(-c3ccc(C(=O)NC4CC4)cc3)nc12

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 4/20 0.46
MKNK2 Q9HBH9 4/20 0.46
MAP4K4 O95819 2/20 0.43
ATR Q13535 2/20 0.41
FYN P06241 1/20 0.40
MAPK14 Q16539 3/20 0.40
CYP2C9 P11712 1/20 0.39
USP7 Q93009 1/20 0.39
SMYD3 Q9H7B4 2/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TTK P33981 1/20 0.39
CHEK2 O96017 1/20 0.38
MET P08581 1/20 0.38
TACR2 P21452 1/20 0.38
CNR1 P21554 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL825839 0.92 MKNK1 (0.44) MKNK1MKNK2MAP4K4ATRMAPK14
SCHEMBL826067 0.91 MKNK1 (0.44) MKNK1MKNK2MAP4K4ATRFYN
SCHEMBL826140 0.91 MKNK1 (0.44) MKNK1MKNK2MAP4K4ATRMAPK14
SCHEMBL826445 0.91 MKNK1 (0.45) MKNK1MKNK2MAP4K4ATRMAPK14
SCHEMBL825946 0.90 MKNK1 (0.44) MKNK1MKNK2MAP4K4ATRMAPK14
SCHEMBL823731 0.89 MKNK1 (0.47) MKNK1MKNK2MAP4K4ATRFYN
SCHEMBL823734 0.87 MKNK2 (0.41) MKNK1MKNK2MAP4K4ATRNPC1
SCHEMBL823680 0.86 MKNK1 (0.49) MKNK1MKNK2MAP4K4MEN1NPC1
SCHEMBL823773 0.85 MKNK2 (0.46) MKNK1MKNK2MAP4K4
SCHEMBL823695 0.85 TLR7 (0.48) MKNK1MKNK2MAP4K4ATRMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC (US) 2009-12-31 US claimed
US-8143394-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2012-03-27 US disclosed
US-8143394-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2012-03-27 US disclosed
US-8143394-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2012-03-27 US disclosed
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC (US) 2009-12-31 US disclosed
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC (US) 2009-12-31 US disclosed
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC (US) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS PNPO, DPYD, PLPBP MKNK1 3271/4885MKNK2 3173/4885MAP4K4 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.